Sio Gene Therapies Announces Reorganization of R&D Group
21 Ottobre 2021 - 11:00PM
Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company
focused on developing gene therapies to radically transform the
lives of patients with neurodegenerative diseases, announced today
that Gavin Corcoran, M.D., Chief Research and Development Officer,
will be leaving the company effective November 12, 2021, to pursue
an opportunity with a private healthcare technology company. Pavan
Cheruvu, M.D., the Company's President and Chief Executive Officer
(CEO), will assume Dr. Corcoran’s responsibilities as Chief
Research and Development Officer going forward. As part of a
realignment of the Company’s research and development organization,
the Company has established two new executive positions, Chief
Medical Officer (CMO) and Senior Vice President of Early
Development and Scientific Affairs, both reporting directly to the
CEO, and has commenced searches to fill these positions.
“Gavin has been instrumental in leading our R&D organization
through a period of growth as we evolved our business model towards
the development of CNS gene therapies,” said Pavan Cheruvu, M.D.,
Chief Executive Officer. “I’m proud of the team he has attracted
who will carry on our patient-focused mission, and on behalf of the
company, I want to thank Gavin for his many contributions to
Sio.”
Dr. Cheruvu continued, “With the continued progress of our gene
therapy programs in the clinic, including positive data announced
earlier today in GM1 gangliosidosis, and plans to expand our
pipeline by investing in next-generation genetic medicines, the
addition of a CMO and SVP of Early Development and Scientific
Affairs will strategically position us for the advancement and
expansion of our pipeline.”
“I have enjoyed the time that I have spent at Sio and I am
extremely proud of the R&D team that we have built. This is one
of the best teams in the industry and they are well positioned to
successfully move these programs to approval. It has been a real
honor to work with our academic collaborators and patient
organizations, and I know that the families and patients that need
these medicines will be in good hands,” said Dr. Corcoran. “We have
come a long way in my three plus years since I joined Pavan at Sio,
and now with a strong leadership team, a promising clinical-stage
gene therapy pipeline, and one of the most experienced teams in
gene therapy development, the future for Sio is bright. I’m looking
forward to seeing Sio achieve continued success.”
About Sio Gene Therapies
Sio Gene Therapies combines cutting-edge science with bold
imagination to develop genetic medicines that aim to radically
improve the lives of patients. Our current pipeline of
clinical-stage candidates includes the first potentially curative
AAV-based gene therapies for GM1 gangliosidosis and
Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal
pediatric conditions caused by single gene deficiencies. We are
also expanding the reach of gene therapy to highly prevalent
conditions such as Parkinson’s disease, which affects millions of
patients globally. Led by an experienced team of gene therapy
development experts, and supported by collaborations with premier
academic, industry and patient advocacy organizations, Sio is
focused on accelerating its candidates through clinical trials to
liberate patients with debilitating diseases through the
transformational power of gene therapies. For more information,
visit www.siogtx.com.
Forward-Looking Statements
This press release contains forward-looking statements for the
purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995 and other federal securities laws.
The use of words such as "expect," "estimate," "may" and other
similar expressions are intended to identify forward-looking
statements. For example, all statements Sio makes regarding costs
associated with its operating activities, funding requirements
and/or runway to meet its upcoming clinical milestones, and timing
and outcome of its upcoming clinical and manufacturing milestones
are forward-looking. All forward-looking statements are based on
estimates and assumptions by Sio’s management that, although Sio
believes to be reasonable, are inherently uncertain. All
forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially from those that
Sio expected. Such risks and uncertainties include, among others,
the impact of the Covid-19 pandemic on our operations; the actual
funds and/or runway required for our clinical and product
development activities and anticipated upcoming milestones; actual
costs related to our clinical and product development activities
and our need to access additional capital resources prior to
achieving any upcoming milestones; the initiation and conduct of
preclinical studies and clinical trials; the availability of data
from clinical trials; the development of a suspension-based
manufacturing process for AXO-Lenti-PD; the scaling up of
manufacturing; the outcome of interactions with regulatory agencies
and expectations for regulatory submissions and approvals; the
continued development of our gene therapy product candidates and
platforms; Sio’s scientific approach and general development
progress; and the availability or commercial potential of Sio’s
product candidates. These statements are also subject to a number
of material risks and uncertainties that are described in Sio’s
most recent Quarterly Report on Form 10-Q filed with the Securities
and Exchange Commission on August 12, 2021, as updated by its
subsequent filings with the Securities and Exchange Commission. Any
forward-looking statement speaks only as of the date on which it
was made. Sio undertakes no obligation to publicly update or revise
any forward-looking statement, whether as a result of new
information, future events or otherwise, except as required by
law.
Contacts:
Media
Josephine Belluardo, Ph.D. LifeSci Communications(646)
751-4361jo@lifescicomms.cominfo@siogtx.com
Investors and Analysts
Parag V. MeswaniSio Gene Therapies Inc.Chief Commercial
Officerinvestors@siogtx.com
Grafico Azioni Sio Gene Therapies (NASDAQ:SIOX)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Sio Gene Therapies (NASDAQ:SIOX)
Storico
Da Giu 2023 a Giu 2024